<DOC>
	<DOCNO>NCT00553657</DOCNO>
	<brief_summary>The purpose study determine standardize fluid intake clinic setting reduce variability individual voiding parameter potentially serve way limit patient exposure initial assessment efficacy compound developed Overactive Bladder .</brief_summary>
	<brief_title>The Study To Test The Effect Standardization Of Fluid Intake In Female Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Eligible participant females 18 year age old , Overactive Bladder evidence daily episode urgency without incontinence , may associate frequency nocturia without bladder pain . At screening , eligible patient must report frequency , define least 8 micturition per 24 hour period . Eligible patient must sign informed consent must meet inclusion exclusion criterion determine screen visit . Any abnormality identify screen examination medical condition circumstance make patient unsuitable participation study base Investigator 's Medical Monitor 's assessment Any contraindication Detrol LA antimuscarinic medication Inability consume 10 cc/kg fluid within 30 minute Regular alcohol consumption average ³7 drinks/week woman ( 1 drink = 100mL wine 285mL beer 30mL hard liquor ) Positive urine drug alcohol screen screening Average blood pressure measurement systolic ≥140 diastolic ≥90 screen screen QTcB value ≥ 450 msec screen Poorlycontrolled diabetes mellitus hypertension , evidence change medication within 2 month prior initiation study History urinary retention gastric retention Known history narrowangle glaucoma History QT prolongation Known reduction hepatic renal function Concomitant Use loop diuretic ( eg . Furosemide ) Concomitant use medication potent inhibitor CYP3A4 Class IA Class III antiarrhythmic medication Patient unable and/or unwilling adhere Lifestyle Guidelines For woman child bear potential , positive serum βhCG screen predose , unwillingness agree adequate contraception time screen completion study : Positive hepatitis C antibody , hepatitis B surface antigen HIV screening . Presence urinary tract infection within 4 week screen . Postvoid residual &gt; 150 mL ( bladder ultrasound ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Experimental Medicine</keyword>
</DOC>